Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
SOUTH SAN FRANCISCO, Calif., July 26, 2017 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on July 24, 2017, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 30,000 shares of the Company’s common stock with a per share exercise price of $30.25, the closing trading price on the grant date, and a restricted stock unit award for 25,000 shares of the Company’s common stock, in each case under the Company’s 2017 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement material to the employee’s entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock option and restricted stock unit award described above) for issuance under the Plan, which was approved by the Company’s Board of Directors in January 2017.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit www.globalbloodtx.com and follow the company on Twitter: @GBT_news.
Contact Information: Myesha Lacy (investors) GBT 650-351-4730 [email protected] Joey Fleury (media) Pure Communications 415-946-1090 [email protected]
